Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

NCT05077436 | Completed Phase 1 FDA Drug

• 2 other identifiers: VIT-2763-CP-1032021-003187-27
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

Two different vamifeport oral formulations will be administered in fed and fasted state to assess the vamifeport food-drug interaction and to assess the relative bioavailability (the proportion of drug entering the circulation) of 2 different vamifeport oral formulations in healthy adult participants. Participants will be randomly allocated to one of four treatment sequences, with four dosing periods each, where different combinations of both formulations will be administered following fasted and fed state. The total study duration for each participant is up to 7 weeks and 4 days.

Conditions

Healthy

Outcome Measures

Primary Outcomes (3)

• Area under the plasma concentration versus time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-last) of vamifeport

  Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

• Area under the plasma concentration versus time curve from time 0 extrapolated to infinite time (AUC0-infinity) of vamifeport

  Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

• Maximum observed concentration (Cmax) of vamifeport

  Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

Secondary Outcomes (5)

• Time of maximum vamifeport plasma concentration (Tmax)

  Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

• Apparent terminal disposition phase half-life (tl/2)

  Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

• Apparent terminal disposition phase rate constant

  Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

• Apparent total clearance

  Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

• Apparent volume of distribution during the terminal disposition phase

  Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

Study Arms (4)

Sequence 1

EXPERIMENTAL

Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fasted state receive Vamifeport Formulation 1 * Day 5: Participants in fed state receive Vamifeport Formulation 1 * Day 9: Participants in fed state receive Vamifeport Formulation 2 * Day 13: Participants in fasted state receive Vamifeport Formulation 2

Drug: Vamifeport Formulation 1; Drug: Vamifeport Formulation 2

Sequence 2

EXPERIMENTAL

Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fed state receive Vamifeport Formulation 1 * Day 5: Participants in fasted state receive Vamifeport Formulation 2 * Day 9: Participants in fasted state receive Vamifeport Formulation 1 * Day 13: Participants in fed state receive Vamifeport Formulation 2

Drug: Vamifeport Formulation 1; Drug: Vamifeport Formulation 2

Sequence 3

EXPERIMENTAL

Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fasted state receive Vamifeport Formulation 2 * Day 5: Participants in fed state receive Vamifeport Formulation 2 * Day 9: Participants in fed state receive Vamifeport Formulation 1 * Day 13: Participants in fasted state receive Vamifeport Formulation 1

Drug: Vamifeport Formulation 1; Drug: Vamifeport Formulation 2

Sequence 4

EXPERIMENTAL

Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fed state receive Vamifeport Formulation 2 * Day 5: Participants in fasted state receive Vamifeport Formulation 1 * Day 9: Participants in fasted state receive Vamifeport Formulation 2 * Day 13: Participants in fed state receive Vamifeport Formulation 1

Drug: Vamifeport Formulation 1; Drug: Vamifeport Formulation 2

Interventions

Vamifeport Formulation 1 DRUG

Vamifeport Formulation 1 is available as 60 mg oral capsules

Sequence 1; Sequence 2; Sequence 3; Sequence 4

Vamifeport Formulation 2 DRUG

Vamifeport Formulation 2 is available as 60 mg oral capsules

Sequence 1; Sequence 2; Sequence 3; Sequence 4

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy participant. Healthy status defined by the Investigator.
• A body weight between 50 and 100 kg inclusive at screening.
• Non-smokers, or former smokers.
• Both female and male participants must agree to comply with the birth control requirements for the study.
• Ability to understand the requirements of the study and abide by the study restrictions, and agreement to return for the required assessments.

You may not qualify if:

• History of clinically significant gastrointestinal, cardiovascular, musculoskeletal, endocrine, neurological, hematological, psychiatric, renal, hepatic, bronchopulmonary, allergic or lipid metabolism disorders, cancer, or drug hypersensitivity.
• Any clinically relevant abnormal 12-lead ECG finding during screening or prior to randomization.
• A clinically relevant history of drug or alcohol misuse or abuse within 2 years prior to screening.
• Positive qualitative or semi-quantitative test for drugs of abuse positive cotinine screen (used to detect recent nicotine use), or alcohol breath test at screening (Visit 1) or Study Day -1 (Visit 2). Use of any of these agents will be not permitted during study participation.
• Strenuous physical exercise within the 1 week prior to Visit 2/Study Day -1 admission, and until completion of safety follow-up assessments are completed.
• Female participants who are pregnant or breastfeeding.
• Any concomitant medication (including herbal remedies and vitamins) taken within 2 weeks prior to Visit 2.
• Concomitant use of hormonal contraceptives (contraception associated with inhibition of ovulation), which are metabolized through cytochrome P450 (CYP) 3A4.
• Any other investigational drug.
• Blood draw or blood donation of ≥20 to \<200 ml within 2 weeks, ≥200 to \<400 ml within 4 weeks, or ≥400 ml within 12 weeks (male) or within 16 weeks (female) prior to Visit 2.

Sponsors & Collaborators

• Vifor (International) Inc.: lead

Study Sites (1)

Labcorp Clinical Research Unit Ltd.

Leeds, LS2 9LH, United Kingdom

Location

Study Officials

• Peter Szecsödy, MD

  Clinical Research Director

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 20, 2021
• First Posted: October 14, 2021
• Study Start: October 14, 2021
• Primary Completion: December 29, 2021
• Study Completion: January 5, 2022
• Last Updated: August 17, 2022

Record last verified: 2022-01

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)